山东步长制药股份有限公司关于控股子公司药品生产许可证变更的公告

Core Viewpoint - The announcement highlights that Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. has received approval from the Sichuan Provincial Drug Administration to change the production scope of its drug manufacturing license, which is expected to positively impact the company's future operations [1][2]. Group 1: Drug Production License Details - The company Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. has received a license to change its production scope to include therapeutic biological products, specifically the injection of recombinant anti-vascular endothelial growth factor receptor 2 (VEGFR2) human monoclonal antibody, limited to registration and declaration use [1]. - The license number is 川20220555, and it is valid until February 16, 2027 [1]. Group 2: Impact on the Company - The change in the drug production license is beneficial for the company as it optimizes the production structure and helps maintain stable production capacity to meet market demand [2]. - The high-tech and high-risk nature of pharmaceutical products means that the development and production process is lengthy and complex, which may be influenced by various uncertainties [2].